ReviewRegenerative therapy2025
Culturing Potential: advances in ex vivo cell culture systems for haematopoietic cell-based regenerative therapies.
Review in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stem-cell derived therapies are an essential pillar in the field of regenerative medicine, utilising stem cell self-renewal and multipotent or pluripotent differentiation capabilities to give rise to functional, specialised cells to repair and restore tissue function. Haematopoietic cell therapies have been pivotal to the development of the regenerative medicine field and continue to hold significant promise enabled by recent technical innovation in cell culture approaches that have expanded their therapeutic potential. The development of novel cell culture protocols that allow for the standardised ex vivo expansion of haematopoietic stem cells (HSCs) has facilitated the exploration of umbilical cord blood allogeneic HSC transplantation. Directed differentiation protocols of HSCs, embryonic stem cells and induced pluripotent stem cells, to selectively produce a desired haematopoietic cell type in a donor-independent manner, has broadened the scope for haematopoietic cell-based regenerative therapy. Furthermore, the integration of genome modification or gene editing with these protocols have allowed for corrective autologous HSC transplantation as well as the ability to confer haematopoietic cells with enhanced or novel therapeutic functions. Despite this, realising large-scale clinical translation remains challenging. Current efforts aim to move towards chemically defined culture systems, improving the efficiency and reproducibility of lineage-specific differentiation with an emphasis on compatibility with genome modification and gene-editing protocols for the scalable production of high-quality, efficacious and safe cellular therapies. In this review, we summarise the key milestones and technical advancements in the field in addition to the outstanding questions to be addressed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.